Cover Image
市場調查報告書

HIV治療藥的全球市場:2015年∼2019年

Global HIV Drugs Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 226022
出版日期 內容資訊 英文 84 Pages
訂單完成後即時交付
價格
Back to Top
HIV治療藥的全球市場:2015年∼2019年 Global HIV Drugs Market 2015-2019
出版日期: 2015年10月14日 內容資訊: 英文 84 Pages
簡介

全球HIV治療藥市場,預計從2014年到2019年以4.52%的年複合成長率成長。

本報告提供全球HIV治療藥市場相關調查、市場規模與其預測、市場成長要素和課題、主要供應商簡介等系統性資訊。

第1章 摘要整理

第2章 調查範圍

第3章 市場調查手法

第4章 簡介

第5章 市場形勢

  • 市場概要
  • 市場規模、預測
  • 波特的五力分析

第6章 市場區隔:各類藥物

第7章 全球多級組合藥物市場

第8章 全球核苷逆轉印酵素抑制劑市場

第9章 全球非核苷逆轉印酵素抑制劑市場

第10章 全球蛋白分解酵素抑制劑市場

第11章 全球融合抑制劑市場

第12章 全球侵入抑制劑市場:CCR5受體隔斷劑市場

第13章 全球HIV整合酶鏈轉移抑制劑

第14章 地區區分

  • 全球HIV治療藥市場區隔:各地區

第15章 市場成長的促進要素

  • 資金的增加
  • 患者人口的增加
  • 醫療的未滿足需求
  • 政府的舉措

第16章 成長因素的影響

第17章 市場課題

  • 專利的失效
  • 社會污名
  • 治療藥的副作用
  • 疾病診斷的併發症

第18章 促進要素、課題的影響

第19章 市場趨勢

  • 社會認識的上升
  • 策略性聯盟
  • 新的方法

第20章 美國政府:HIV資金

第21章 業者情勢

  • 競爭情形
  • 市場佔有率分析
  • 其他有潛力的供應商

第22章 主要供應商分析

  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck

第23章 附錄

第24章 關於Technavio

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR7469

About HIV

HIV is a type of retrovirus that causes infection in human beings. AIDS is a life-threatening disease caused by this virus. In this disease certain white blood cells (lymphocytes) are destroyed, resulting in the loss of the body's ability to protect itself against infections. The major route of transmission of HIV infection is unprotected sex, contaminated needle, breast milk, and infected blood. HIV attacks the body's white blood cells, specifically a subset called CD4 or helper T cells. The anti-retroviral therapy is used to treat the patient and help the immune system fight the infection. This is mainly used to keep the level of the HIV low in the body.

Technavio's analysts forecast the global HIV drugs market to grow at a CAGR of 4.52% over the period 2014-2019.

Covered in this report

This report covers the present scenario and the growth prospects of the global HIV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic and branded drugs and the expected launch of drug candidates used in the treatment of HIV infection.

Based on the class of drugs, the market is segmented as follows:

  • Multi-class combination products
  • Nucleoside reverse transcriptase inhibitors
  • Non-nucleoside reverse transcriptase inhibitors
  • Protease inhibitors
  • Fusion inhibitors
  • Entry inhibitors - CCR5 co-receptor antagonist
  • HIV integrase strand transfer inhibitors

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. The vendor landscape section includes a market share analysis of the major vendors along with the competitive performances of their product portfolios. In addition, the report discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends emerging in the market.

Technavio's report, Global HIV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key regions

  • Americas
  • APAC
  • EMEA

Key vendors

  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck

Other Prominent Vendors

  • AbbVie
  • AstraZeneca
  • Boehringer Ingelheim
  • Cipla
  • Daiichi Sankyo
  • Emcure
  • F. Hoffmann-La Roche
  • Hetero Drugs
  • Mylan
  • Pfizer
  • Shionogi
  • Teva Pharmaceutical Industries

Market driver

  • Inflow of funds
  • For a full, detailed list, view our report

Market challenge

  • Patent expiries
  • For a full, detailed list, view our report

Market trend

  • Increasing public awareness
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 06: Market segmentation by drug class

PART 07: Global multi-class combination products market

  • Global multi-class combination products market

PART 08: Global nucleoside reverse transcriptase inhibitors market

  • Global nucleoside reverse transcriptase inhibitors market

PART 09: Global non-nucleoside reverse transcriptase inhibitors market

  • Global non-nucleoside reverse transcriptase inhibitors market

PART 10: Global protease inhibitors market

  • Global protease inhibitors market

PART 11: Global fusion inhibitors market

  • Global fusion inhibitors market

PART 12: Global entry inhibitors - CCR5 co-receptor antagonist market

  • Global entry inhibitors - CCR5 co-receptor antagonist market

PART 13: Global HIV integrase strand transfer inhibitors market

  • Global HIV integrase strand transfer inhibitors market

PART 14: Geographical segmentation

  • Global HIV drugs market segmentation by geography

PART 15: Market drivers

  • Increased funding
  • Rise in patient population
  • Unmet medical needs
  • Initiatives by governments

PART 16: Impact of drivers

PART 17: Market challenges

  • Expiry of patents
  • Associated social stigma
  • Side effects of drugs
  • Complications in disease diagnosis

PART 18: Impact of drivers and challenges

PART 19: Market trends

  • Rise in public awareness
  • Strategic alliances
  • Novel approaches

PART 20: US Government: Funding for HIV

PART 21: Vendor landscape

  • Competitive scenario
  • Market share analysis
  • Other prominent vendors

PART 22: Key vendor analysis

  • Bristol-Myers Squibb
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck

PART 23: Appendix

  • List of abbreviations

PART 24: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Global HIV drugs market 2014-2019 ($ millions)
  • Exhibit 03: Five forces analysis
  • Exhibit 04: Global HIV drugs market segmentation by drug class 2014
  • Exhibit 05: Global HIV drugs market segmentation by drug class 2014-2019 ($ millions)
  • Exhibit 06: Global multi-class combination products market 2014-2019 ($ millions)
  • Exhibit 07: Global nucleoside reverse transcriptase inhibitors market 2014-2019 ($ millions)
  • Exhibit 08: Global non-nucleoside reverse transcriptase inhibitors market 2014-2019 ($ millions)
  • Exhibit 09: Global protease inhibitors market 2014-2019 ($ millions)
  • Exhibit 10: Global fusion inhibitors market 2014-2019 ($ millions)
  • Exhibit 11: Global entry inhibitors - CCR5 co-receptor antagonist market 2014-2019 ($ millions)
  • Exhibit 12: Global HIV integrase strand transfer inhibitors market 2014-2019 ($ millions)
  • Exhibit 13: Global HIV drugs market segmentation by geography 2014
  • Exhibit 14: Global HIV drugs market segmentation by geography 2014-2019 ($ millions)
  • Exhibit 15: HIV drugs market in Americas 2014-2019 ($ millions)
  • Exhibit 16: HIV drugs market in EMEA 2014-2019 ($ millions)
  • Exhibit 17: HIV drugs market in APAC 2014-2019 ($ millions)
  • Exhibit 18: Assistance from donor governments for HIV treatment 2013
  • Exhibit 19: Global HIV statistics 2014
  • Exhibit 20: Impact of drivers
  • Exhibit 21: Impact of drivers and challenges
  • Exhibit 22: Funding by the US government for HIV 2010-2016 ($ billions)
  • Exhibit 23: Funding by the US government for domestic treatment and care of HIV 2010-2016 ($ billions)
  • Exhibit 24: Bristol-Myers Squibb: Revenue of Reyataz 2012-2014 ($ billions)
  • Exhibit 25: Bristol-Myers Squibb: Revenue of Sustiva 2012-2014 ($ billions)
  • Exhibit 26: Gilead Sciences: Revenue of Stribild 2012-2014 ($ millions)
  • Exhibit 27: Gilead Sciences: Revenue of Truvada 2012-2014 ($ billions)
  • Exhibit 28: Gilead Sciences: Revenue of Emtriva 2012 and 2013 ($ millions)
  • Exhibit 29: Gilead Sciences: Revenue of Atripla 2012-2014 ($ billions)
  • Exhibit 30: Gilead Sciences: Revenue of Complera/Eviplera 2012-2014 ($ millions)
  • Exhibit 31: Gilead Sciences: Revenue of Viread 2012-2014 ($ millions)
  • Exhibit 32: GlaxoSmithKline: Revenue of Combivir 2012-2014 ($ millions)
  • Exhibit 33: GlaxoSmithKline: Revenue of Trizivir 2012-2014 ($ millions)
  • Exhibit 34: GlaxoSmithKline: Revenue of Agenerase and Lexiva 2012-2014 ($ millions)
  • Exhibit 35: GlaxoSmithKline: Revenue of Tivicay 2013-2014 ($ millions)
  • Exhibit 36: Johnson & Johnson: Revenue of Edurant 2012-2014 ($ millions)
  • Exhibit 37: Johnson & Johnson: Revenue of Prezista 2012-2014 ($ billions)
  • Exhibit 38: Merck: Revenue of Isentress 2012-2014 ($ billions)
Back to Top